(CYBN) – Business Wire
-
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
-
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
-
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
-
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
-
Announces Oversubscribed Private Placement of U.S. $150 Million
-
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
-
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
-
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
-
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
-
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
-
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
-
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
-
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
-
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
-
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
-
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
-
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
-
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
-
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
-
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
-
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
-
Cybin Announces up to US$64 Million Offering of Units
-
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
-
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
-
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms Aft
-
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
-
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
-
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
-
Small Pharma Obtains Final Order Approving Arrangement
-
Cybin Announces Results of Annual and Special Meeting of Shareholders
-
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
-
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
-
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
-
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
-
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
-
Cybin to Participate in the Cantor Global Healthcare Conference
-
Cybin Announces Date of Annual and Special Meeting of Shareholders
-
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
-
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
-
Cybin to Acquire Small Pharma Inc.
-
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
-
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial
-
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
-
Cybin Reports First Quarter Financial Results and Recent Business Highlights
-
Cybin Announces Closing of Overnight Marketed Public Offering of Units
-
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
-
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
Back to CYBN Stock Lookup
